C4 Therapeutics (CCCC) Debt Ratio (2020 - 2023)

C4 Therapeutics' Debt Ratio history runs 4 years deep, the most recent figure standing at 0.06 for Q2 2023.

• On a quarterly basis, Debt Ratio rose 144.06% year-over-year to 0.06 in Q2 2023; TTM through Jun 2023 was 0.06, a 144.06% increase from a year earlier, with the FY2022 full-year figure at 0.03, up 25.42% from the prior year.
• Debt Ratio advanced to 0.06 in Q2 2023 per CCCC's latest filing, from 0.04 in the prior quarter.
• Across five years, Debt Ratio topped out at 0.06 in Q2 2023 and bottomed at 0.02 in Q2 2021.
• The 4-year median for Debt Ratio is 0.02 (2020), against an average of 0.03.
• Across the five-year window, Debt Ratio slumped 51.64% in 2021 and soared 144.06% in 2023, its largest moves.
• Year by year, Debt Ratio stood at 0.03 in 2020, then retreated by 15.42% to 0.02 in 2021, then climbed by 25.42% to 0.03 in 2022, then jumped by 106.82% to 0.06 in 2023.
• Per Business Quant, the three latest CCCC Debt Ratio figures stand at 0.06 (Q2 2023), 0.04 (Q1 2023), and 0.03 (Q4 2022).